NCT05169853View on ClinicalTrials.gov

Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer

Active, not recruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2024

Conditions
Triple Negative Breast CancerHER2-positive Breast Cancer
Trial Locations (1)

7154411

Ain Shams University Clinical Oncology Department, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER